Hypofibrinolytic State in Subjects with Type 2 Diabetes Mellitus Aggravated by the Metabolic Syndrome before Clinical Manifestations of Atherothrombotic Disease.
Background. Metabolic and genetic factors induce plasminogen activator inhibitor type-1 (PAI-1) overexpression; higher PAI-1 levels decrease fibrinolysis and promote atherothrombosis. Aim. To assess PAI-1 antigen levels among subjects with type 2 diabetes mellitus (T2DM) plus Metabolic Syndrome (Met...
| Published in: | BioMed Research International Vol. 2017; pp. 1 - 10 |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Format: | research tables/charts Journal Article |
| Published: |
Wiley-Blackwell
2/8/2017
|
| Online Access: | View this record in EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=121185195&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 121185195 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 23146133 FT2T jtl: BioMed Research International issn: 23146133 maglogo: N pubinfo: dt: 2/8/2017 vid: 2017 pid: 480 pub: Wiley-Blackwell place: Malden, Massachusetts artinfo: ui: 121185195 121185195 121185195 10.1155/2017/6519704 121185195 ppf: 1 ppct: 9 formats: fmt: @attributes: type: P tig: atl: Hypofibrinolytic State in Subjects with Type 2 Diabetes Mellitus Aggravated by the Metabolic Syndrome before Clinical Manifestations of Atherothrombotic Disease. aug: au: Aburto-Mejía, Elsa Santiago-Germán, David Martínez-Marino, Manuel María Eugenia Galván-Plata Almeida-Gutiérrez, Eduardo López-Alarcón, Mardia Hernández-Juárez, Jesús Alvarado-Moreno, Antonio Leaños-Miranda, Alfredo Majluf-Cruz, Abraham Isordia-Salas, Irma affil: Servicio de Medicina Interna, UMAE Hospital de Especialidades, CMN Siglo XXI, Instituto Mexicano del Seguro Social, Ciudad de México, Mexico sug: subj: Metabolic Syndrome X Mexico Diabetes Mellitus, Type 2 Mexico Thrombosis Cross Sectional Studies Fibrinolysis Genotype Hypertension Polymorphism, Genetic Triglycerides Cardiovascular Risk Factors Enzyme-Linked Immunosorbent Assay DNA Polymerase Chain Reaction T-Tests One-Way Analysis of Variance Pearson's Correlation Coefficient Spearman's Rank Correlation Coefficient Multiple Linear Regression Data Analysis Software P-Value Female Middle Age Aged Male Mexico Confidence Intervals Biological Markers Funding Source Middle Aged: 45-64 years Aged: 65+ years Female Male ab: Background. Metabolic and genetic factors induce plasminogen activator inhibitor type-1 (PAI-1) overexpression; higher PAI-1 levels decrease fibrinolysis and promote atherothrombosis. Aim. To assess PAI-1 antigen levels among subjects with type 2 diabetes mellitus (T2DM) plus Metabolic Syndrome (MetS) before clinical manifestations of atherothrombosis and the contribution of metabolic factors and 4G/5G polymorphism of PAI-1 gene on the variability of PAI-1. Methods. We conducted an observational, cross-sectional assay in a hospital in Mexico City from May 2010 to September 2011. MetS was defined by the International Diabetes Federation criteria. PAI-1 levels and 4G/5G polymorphism were determined by ELISA and PCR-RFLP analysis. Results. We enrolled 215 subjects with T2DM plus MetS and 307 controls. Subjects with T2DM plus MetS had higher PAI-1 levels than the reference group (58.4 ± 21 versus 49.9 ± 16 ng/mL, p=0.026). A model with components of MetS explained only 12% of variability on PAI-1 levels (R2 = 0.12; p=0.001), with β=0.18 (p=0.03) for hypertension, β=-0.16 (p=0.05) for NL HDL-c, and β=0.15 (p=0.05) for NL triglycerides. Conclusion. Subjects with T2DM plus MetS have elevated PAI-1 levels before clinical manifestations of atherothrombotic disease. Metabolic factors have a more important contribution than 4G/5G polymorphism on PAI-1 plasma variability. pubtype: Academic Journal doctype: research tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|